Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03845270 (Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer), which is not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials.Medicine · 2022Pooled it
- First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.Nature medicine · 2023Trial
- Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).BMC medicine · 2022Trial
- Trastuzumab Deruxtecan inThe New England journal of medicine · 2022Trial
- Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.Future oncology (London, England) · 2026Review
- Case Report: Successful trastuzumab deruxtecan rechallenge after disease progression in a pretreatedFrontiers in oncology · 2026Article
- Case Report: Complete metabolic responses to trastuzumab-deruxtecan in HER2-altered solid tumors: two illustrative cases.Frontiers in immunology · 2026Article
- Exceptional response to furmonertinib in lung adenocarcinoma harboring HER2 exon 20 insertion mutation: a case report.Frontiers in oncology · 2026Article
- Evolving treatment strategies for HER2-altered non-small-cell lung cancer: the rise of TKIs and ADCs.Frontiers in oncology · 2026Review
- Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions.International journal of molecular sciences · 2025Review
- Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Biomolecules · 2025Review
- Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.British journal of cancer · 2025Article
- [Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer with HER2 Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top.Molecules (Basel, Switzerland) · 2025Review
- Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations.Journal of translational medicine · 2025Review
- Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP).The oncologist · 2025Article
- Review
- HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities.Frontiers in oncology · 2025Review
- The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.Therapeutic advances in medical oncology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
19 authors at 15 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose
methodsThe IFCT 1703-R2D2 trial is a multicenter, nonrandomized phase II study. Patients with
resultsForty-five patients were enrolled and treated. The median age was 64.5 years (range, 31-84 years), 35% were smokers, 72% were females, 15% had an Eastern Cooperative Oncology Group performance status of 2, and 30% had brain metastases. The objective response rate was 29% (n = 13), and 58% had stable disease (n = 26). The median progression-free survival was 6.8 months (95% CI, 4.0 to 8.5). The median duration of response in patients with a confirmed response (n = 13) was 11 months (95% CI, 2.9 to 14.9). Grade 3/4 treatment-related adverse events were observed in 64% of the patients. No patient discontinued treatment because of toxicity. The most frequent grade ≥ 3 treatment-related adverse events were neutropenia (33%), diarrhea (13%), and anemia (9%).
conclusionTriple therapy with trastuzumab, pertuzumab, and docetaxel is feasible and effective for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.